Entering text into the input field will update the search result below

Alnylam Q1 ONPATTRO sales $26.3M

  • Alnylam Pharmaceuticals (NASDAQ:ALNY -5.7%) Q1 results: Revenues: $33.3M (+52.1%); ONPATTRO: $26.3M; Net revenues from collaborators: $7M.
  • Net Loss: ($181.9M) (-28.8%); Loss Per Share: ($1.73) (-22.7%); Non-GAAP Net Loss: ($149.9M) (-23.3%); Non-GAAP Loss Per Share: ($1.42) (-16.4%).
  • 2019 Guidance: R&D expenses: $550M - 590M from $520M - 560M; SG&A expenses: $390M - 410M from $390M - 420M.
  • Previously: Alnylam Pharmaceuticals beats by $0.38, beats on revenue (May 1)

Recommended For You

More Trending News

About ALNY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ALNY--
Alnylam Pharmaceuticals, Inc.